Spotlight: COVID-19 Pathogenic Priming Research Published


IPAK research recasts the very poorly named "Immune Enhancement" as "Pathogenic Priming".  

Importantly, the study results (new results from IPAK) point to the very high likelihood of autoimmunity against specific tissues that would be induced by vaccination against SARS-CoV-2.  The tissues match those we see issues with in COVID-19 - but also point to a large number and % of potentially targeted human immune system proteins - a first finding by IPAK.

The study supports the idea the we should treat SARS-CoV-2 as an autoimmune disorder, and of course very strongly supports the absolute requirement of animal safety studies.  

Note that the article concludes:

"SARS-CoV-2 has some unexplained pathogenic features that might be related to the table of putative pathogenic priming peptides. Exposure to these specific peptides - via either infection or vaccination - might prime patients for increased risk of enhanced pathogenicity during future exposure due either to future pandemic or outbreaks or via universal vaccination programs. While the mechanisms pathogenesis of COVID-19 are still poorly understood, the morbidity and mortality of SARS has been extensively studied. Thus, the involvement of pathogenic priming in re-infection by COVID-19 is a theoretical possibility; of course no vaccine against SARS-CoV-2 has yet been tested in animals and therefore we do not yet know if pathogenic priming is in fact expected. Such studies should be undertaken before use of any vaccine against SARS-CoV-2 is used in humans.   "

The article also points to speciifc epitopes that should be excluded from any SARS-CoV-2/COVID-19 vaccine to avoid induction of autoimmunity.  Such a step might reduce the risk of disease enhancement via pathogenic priming.

Study link: https://www.sciencedirect.com/science/article/pii/S2589909020300186?via%3Dihub 

Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity James Lyons-Weiler PII: S2589-9090(20)30018-6 DOI: https://doi.org/10.1016/j.jtauto.2020.100051 Reference: JTAUTO 100051 To appear in: Journal of Translational Autoimmunity Received Date: 9 March 2020 Revised Date: 31 March 2020 Accepted Date: 2 April 2020 Please cite this article as: J. Lyons-Weiler, Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity, Journal of Translational Autoimmunity, https:// doi.org/10.1016/j.jtauto.2020.100051


Our study providing an estimate of a pediatric dose limit has people talking. Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation More research coming in 2020!

The Institute for Pure and Applied Knowledge is a not-for-profit organization that exists to perform scientific research in the public interest. We use the principles and practices of scientific research to help individual researchers, research teams, consortia, and companies push their project through roadblocks, or map their way around them via evidence-based alternatives. We provide independent views and intellectual effort on scientific progress in three main areas:

  • Helping investigators in their efforts to reduce human pain & suffering through biomedical and related forms of scientific research.
  • Helping investigators increase their understanding of the universe using science as a way of knowing.
  • Educating the public in robust and reliable advances in medicine and science.

Our activities are varied, and include:

  • Conducting and publishing independent and objective nonpartisan analyses, studies, and research on legislative issues that impact public health and scientific progress in light of peer-reviewed and published scientific findings.
  • Providing support in many forms to endeavors that advance understanding via science (publications, consortia, conferences).
  • Providing support to progress in science in specific critical areas that are likely to reduce human pain and suffering - and we go the extra mile to help make those successes in translation happen.
  • Voicing informed opinions and issues on select government agency and court rulings, and actions and positions taken by other government agencies that influence healthcare practice and affect public health.

IPAK: Bringing knowledge & people together in the pursuit of successes in research via progressive science.

IPAK is a not-for-profit organization funded by private donations from the public.

To learn more about IPAK, write to us.

IPAK is registered as a Domestic Not-For-Profit Organizations in the Commonwealth of Pennsylvania. We as in PHASE II of our application process for 501c3 status. You can help with your gift or donation!